Ahmad E, Lim S, Lamptey R, Webb DR, Davies MJ (2022) Type 2 diabetes. Lancet 400:1803–1820. https://doi.org/10.1016/S0140-6736(22)01655-5

Article  PubMed  Google Scholar 

Ala M, Moheb AM (2024) The blood pressure-lowering property of subcutaneous semaglutide: a systematic review, meta-analysis, and meta-regression. J Endocrinol Invest. https://doi.org/10.1007/s40618-024-02459-3

Article  PubMed  Google Scholar 

Andreadis P, Karagiannis T, Malandris K, Avgerinos I, Liakos A, Manolopoulos A, Bekiari E, Matthews DR, Tsapas A (2018) Semaglutide for type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab 20:2255–2263. https://doi.org/10.1111/dom.13361

Article  CAS  PubMed  Google Scholar 

Azoulay L, Filion KB, Platt RW, Dahl M, Dormuth CR, Clemens KK, Durand M, Juurlink DN, Targownik LE, Turin TC, Paterson JM, Ernst P (2016) Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study. BMJ 352:i581. https://doi.org/10.1136/bmj.i581

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brabletz S, Schuhwerk H, Brabletz T, Stemmler MP (2021) Dynamic EMT: a multi-tool for tumor progression. Embo J. https://doi.org/10.15252/embj.2021108647

Article  PubMed  PubMed Central  Google Scholar 

Capehorn MS, Catarig AM, Furberg JK, Janez A, Price HC, Tadayon S, Verges B, Marre M (2020) Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab 46:100–109. https://doi.org/10.1016/j.diabet.2019.101117

Article  CAS  PubMed  Google Scholar 

Cargnello M, Roux PP (2011) Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev 75:50–83. https://doi.org/10.1128/MMBR.00031-10

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chang WS, Tsai CW, Yang JS, Hsu YM, Shih LC, Chiu HY, Bau DT, Tsai FJ (2021) Resveratrol inhibited the metastatic behaviors of cisplatin-resistant human oral cancer cells via phosphorylation of ERK/p-38 and suppression of MMP-2/9. J Food Biochem 45:e13666. https://doi.org/10.1111/jfbc.13666

Article  CAS  PubMed  Google Scholar 

Chao AM, Tronieri JS, Amaro A, Wadden TA (2023) Semaglutide for the treatment of obesity. Trends Cardiovasc Med 33:159–166. https://doi.org/10.1016/j.tcm.2021.12.008

Article  CAS  PubMed  Google Scholar 

Chen BD, Zhao WC, Jia QA, Zhou WY, Bu Y, Wang ZZ, Wang F, Wu WJ, Wang Q (2013) Effect of the GLP-1 analog exendin-4 and oxaliplatin on intrahepatic cholangiocarcinoma cell line and mouse model. Int J Mol Sci 14:24293–24304. https://doi.org/10.3390/ijms141224293

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen JC, Hsieh MC, Lin SH, Lin CC, Hsi YT, Lo YS, Chuang YC, Hsieh MJ, Chen MK (2017) Coronarin D induces reactive oxygen species-mediated cell death in human nasopharyngeal cancer cells through inhibition of p38 MAPK and activation of JNK. Oncotarget. https://doi.org/10.18632/oncotarget.22444

Article  PubMed  PubMed Central  Google Scholar 

Dhillon S (2018) Semaglutide: first global approval. Drugs 78:275–284. https://doi.org/10.1007/s40265-018-0871-0

Article  CAS  PubMed  Google Scholar 

Dhillon AS, Hagan S, Rath O, Kolch W (2007) MAP kinase signalling pathways in cancer. Oncogene 26:3279–3290. https://doi.org/10.1038/sj.onc.1210421

Article  CAS  PubMed  Google Scholar 

Eftekhari S, Montazeri H, Tarighi P (2020) Synergistic anti-tumor effects of Liraglutide, a glucagon-like peptide-1 receptor agonist, along with Docetaxel on LNCaP prostate cancer cell line. Eur J Pharmacol 878:173102. https://doi.org/10.1016/j.ejphar.2020.173102

Article  CAS  PubMed  Google Scholar 

ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, On BOTA (2023) 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023. Diabetes Care 46:S140–S157. https://doi.org/10.2337/dc23-S009

Article  CAS  PubMed  Google Scholar 

Heise T (2022) Novel drugs for diabetes therapy. Handb Exp Pharmacol 274:415–438. https://doi.org/10.1007/164_2021_574

Article  CAS  PubMed  Google Scholar 

Holst JJ, Gromada J (2004) Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 287:E199–E206. https://doi.org/10.1152/ajpendo.00545.2003

Article  CAS  PubMed  Google Scholar 

Hu X, Wu J, Xiong H, Zeng L, Wang Z, Wang C, Huang D, Zhang T, Peng Y, Chen W, Xia K, Su T (2022) Type 2 diabetes mellitus promotes the proliferation, metastasis, and suppresses the apoptosis in oral squamous cell carcinoma. J Oral Pathol Med 51:483–492. https://doi.org/10.1111/jop.13244

Article  CAS  PubMed  Google Scholar 

Hu EH, Tsai ML, Lin Y, Chou TS, Chen TH (2024) A review and meta-analysis of the safety and efficacy of using glucagon-like peptide-1 receptor agonists. Medicina (Kaunas). https://doi.org/10.3390/medicina60030357

Article  PubMed  PubMed Central  Google Scholar 

Huang Y, Hong W, Wei X (2022) The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J Hematol Oncol 15:129. https://doi.org/10.1186/s13045-022-01347-8

Article  PubMed  PubMed Central  Google Scholar 

Huang S, Zhang J, Qiao Y, Pathak JL, Zou R, Piao Z, Xie S, Liang J, Ouyang K (2024) CHRDL1 inhibits OSCC metastasis via MAPK signaling-mediated inhibition of MED29. Mol Med 30:187. https://doi.org/10.1186/s10020-024-00956-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ibrahim SS, Ibrahim RS, Arabi B, Brockmueller A, Shakibaei M, Busselberg D (2024) The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer. Cancer Metastasis Rev. https://doi.org/10.1007/s10555-024-10192-9

Article  PubMed  PubMed Central  Google Scholar 

Iwaya C, Nomiyama T, Komatsu S, Kawanami T, Tsutsumi Y, Hamaguchi Y, Horikawa T, Yoshinaga Y, Yamashita S, Tanaka T, Terawaki Y, Tanabe M, Nabeshima K, Iwasaki A, Yanase T (2017) Exendin-4, a glucagonlike peptide-1 receptor agonist, attenuates breast cancer growth by inhibiting NF-kappaB activation. Endocrinology 158:4218–4232. https://doi.org/10.1210/en.2017-00461

Article  CAS  PubMed  Google Scholar 

Ji L, He X, Min X, Yang H, Wu W, Xu H, Chen J, Mei A (2024) Glucagon-like peptide-1 receptor agonists in neoplastic diseases. Front Endocrinol (Lausanne) 15:1465881. https://doi.org/10.3389/fendo.2024.1465881

Article  PubMed  Google Scholar 

Johnson DE, Burtness B, Leemans CR, Lui V, Bauman JE, Grandis JR (2020) Head and neck squamous cell carcinoma. Nat Rev Dis Primers 6:92. https://doi.org/10.1038/s41572-020-00224-3

Article  PubMed  PubMed Central  Google Scholar 

Kanda R, Hiraike H, Wada-Hiraike O, Ichinose T, Nagasaka K, Sasajima Y, Ryo E, Fujii T, Osuga Y, Ayabe T (2018) Expression of the glucagon-like peptide-1 receptor and its role in regulating autophagy in endometrial cancer. BMC Cancer 18:657. https://doi.org/10.1186/s12885-018-4570-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Koehler JA, Kain T, Drucker DJ (2011) Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells. Endocrinology 152:3362–3372. https://doi.org/10.1210/en.2011-1201

Article  CAS  PubMed